Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks Stock plan guidance
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Revenues beat guidance at Oxford Nanopore, shares spark
(Sharecast News) - Shares in Oxford Nanopore Technologies surged in early trading on Monday, after the FTSE 250 firm said full-year sales had beaten guidance. Updating on year-end trading, the business - a specialist in nanopore-based molecular sensing technology - said revenues were set to come in between £223m and £224m.
That represents a 22% increase on 2024, or a 24% jump on a constant currency basis.
Oxford Nanopore had previously steered for an increase of between 20% and 23% on a constant currency basis.
It also flagged "continued progress" during the year on its path to profitability.
As at 0830 the stock had jumped 8% at 151.6p.
Driving the "strong" 2025 performance was a 60% surge in clinical revenues. All segments saw revenue growth, however, including biopharma - up 30% - and applied industrial, which reported a 27% spike in sales.
The business also confirmed it had ended the year with around £302m in cash, cash equivalents and other liquid investments, ahead of expectations, following improved working capital.
Oxford Nanopore said the higher-than-expected cash provided "continued balance sheet strength to support execution of the group strategy".
Oxford Nanopore, which was founded in 2005 as a spin out from the Oxford University, is due to publish results for the year to 31 December on 2 March.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document or Product Summary document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
